Despite progress in healthcare services for individuals living with sickle cell disease (SCD) in Africa, substantial gaps ...

We can do better. We can build a system that provides coordinated high-quality care to every patient who needs it.

The R21/Matrix-M malaria vaccine offers the highest efficacy in the history of malaria vaccine development as reported by Mehreen Datoo and colleagues.1 The potential for saving the lives of African ...

We thank the authors for their interest in our paper, and their queries. In response to Yue Li and Guangsen Liu, given the current situation of malaria deaths and cases increasing in recent years,1 it ...

In recent years, new interventions have been developed against malaria, including vaccines that currently are being rolled out for young children in regions where the disease is prevalent.

Malaria is a life-threatening disease caused by Plasmodium parasites, which are spread through the bites of infected mosquitoes. Although malaria is not common in the United States, its global ...

Overall, the life expectancy of patients with SCD is lower than that of persons without SCD. 1 However, life expectancy varies depending on the type of disease, treatments administered, and ...

In early December, international alarm bells went off because of a mysterious disease circulating in a ... flu or rhinoviruses — complicated by malaria as well as widespread malnutrition.

A groundbreaking study has identified a more effective malaria prevention drug for children with sickle cell disease and sickle cell anemia. This could significantly reduce complications and mortality ...

Since then, I think it's fair to say that most people have been nervous about the emergence of the next big infectious disease – be that a virus ... continuing 'slow pandemics' in humans, such as ...

Respiratory symptoms arise from various malaria-related complications, including pulmonary edema and anemia, demanding immediate medical intervention. The unknown mysterious disease that has been ...

Tessera Therapeutics has announced a partnership with the Bill & Melinda Gates Foundation, securing funding of up to $50m to develop an in vivo genetic therapy for sickle cell disease (SCD). The ...